Cytogen chooses Berlex for Quadramet
After months of searching for a new partner to market its bone cancer therapeutic agent Quadramet, radiopharmaceutical firm Cytogen of Princeton, NJ, announced Oct. 29 that it had signed an exclusive license agreement with Berlex Laboratories for the
After months of searching for a new partner to market its bone cancer therapeutic agent Quadramet, radiopharmaceutical firm Cytogen of Princeton, NJ, announced Oct. 29 that it had signed an exclusive license agreement with Berlex Laboratories for the manufacture and sale of the product. The deal covers marketing and sales in North and South America, and the two companies are in the process of securing a long-term supply agreement with Du Pont Pharmaceutical of North Billerica, MA, Cytogens former marketing partner and current contract manufacturer of Quadramet.
Berlex will pay Cytogen $8 million when the supply agreement with Du Pont is finalized. Cytogen will pay half of the money to Du Pont to establish a five-year manufacturing deal. Berlex will also pay royalties to Cytogen on net sales of Quadramet, as well as milestone payments for achieving predetermined sales levels. The Montville, NJ, company expects to begin marketing Quadramet in January 1999. Cytogen plans to conclude phase IV post-approval studies required by the Food and Drug Administration in its clearance of Quadramet.
The Berlex deal closes an interim agreement between Cytogen and Du Pont, in which Du Pont agreed to identify marketing partner candidates for Cytogen (SCAN 10/28/98).
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
